tiprankstipranks
Advertisement
Advertisement

JP:4503 Stock Latest News

Astellas Highlights R&D Strategy While Flagging Market and Development Risks
Company AnnouncementsAstellas Highlights R&D Strategy While Flagging Market and Development Risks
10d ago
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
PremiumCompany Announcements
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
1M ago
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
PremiumCompany Announcements
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
1M ago
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
PremiumCompany Announcements
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
2M ago
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
PremiumRatings
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
2M ago
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
PremiumCompany AnnouncementsAstellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
2M ago
ALPMF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ALPMF Upcoming Earnings Report: What to Expect?
2M ago
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
Premium
Company Announcements
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
4M ago
Astellas Pharma Revises FY2025 Financial Forecasts Upward
PremiumCompany Announcements
Astellas Pharma Revises FY2025 Financial Forecasts Upward
5M ago
Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
5M ago
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
PremiumCompany Announcements
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
6M ago
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
PremiumCompany Announcements
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
7M ago
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
PremiumRatingsAstellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
7M ago
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment
Premium
Company Announcements
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment
8M ago
Astellas Reports Strong Preliminary Sales for IZERVAY™ in Q1 FY2025
Premium
Company Announcements
Astellas Reports Strong Preliminary Sales for IZERVAY™ in Q1 FY2025
9M ago
Astellas Pharma Continues Performance-linked Stock Schemes for Executives
PremiumCompany Announcements
Astellas Pharma Continues Performance-linked Stock Schemes for Executives
11M ago
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
PremiumCompany Announcements
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
11M ago
Astellas Pharma Announces Changes to Board of Directors
PremiumCompany Announcements
Astellas Pharma Announces Changes to Board of Directors
11M ago
Astellas Pharma Reports Record Revenue and Growth
PremiumCompany Announcements
Astellas Pharma Reports Record Revenue and Growth
12M ago
Astellas Pharma Reports Higher Than Expected Financial Results
PremiumCompany AnnouncementsAstellas Pharma Reports Higher Than Expected Financial Results
12M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12M ago
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
Premium
Company Announcements
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >